title: Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review.
abstract: OBJECTIVE
  To identify and critically evaluate evidence from randomized controlled trials for the efficacy of treatments for mucous membrane pemphigoid (MMP)/cicatricial pemphigoid (CP) and epidermolysis bullosa acquisita (EBA).
  
  
  METHODS
  Review of MEDLINE from 1966 through March 2000, EMBASE from 1980 through March 2000, and the Cochrane Controlled Trials Register (February 28, 2001) to identify randomized controlled trials for the efficacy of treatments in MMP/CP and EBA.
  
  
  METHODS
  All randomized controlled trials of therapeutic interventions that included patients with MMP/CP or EBA confirmed by immunofluorescence study findings. All age groups were included.
  
  
  RESULTS
  We found 2 small randomized controlled trials of MMP/CP, both conducted in patients with severe eye involvement. We were not able to identify a randomized controlled trial of therapeutic interventions in EBA.
  
  
  CONCLUSIONS
  There is evidence from 2 small trials that severe ocular CP responds best to treatment with cyclophosphamide, and mild to moderate disease seems effectively suppressed by treatment with dapsone. No treatment recommendations can be made for EBA because to our knowledge no randomized controlled trials are published. Even though systemic corticosteroids are regarded as the gold standard in the treatment of MMP/CP and EBA, there is poor evidence from the literature that they are the best treatment for these diseases.
authors.affiliation: Department of Dermatology, Oxford Radcliffe Hospital, England. G.Kirtschig@vumc.nl
authors.forename: Gudula
authors.initials: G
authors.lastname: Kirtschig
authors.forename: Dédée
authors.initials: D
authors.lastname: Murrell
authors.forename: Fenella
authors.initials: F
authors.lastname: Wojnarowska
authors.forename: Nonhlanhla
authors.initials: N
authors.lastname: Khumalo
mesh_terms: D003520:Cyclophosphamide / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013457:Sulfur Compounds / Q000627:therapeutic use
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D013457:Sulfur Compounds; D003520:Cyclophosphamide; D003622:Dapsone; D011241:Prednisone